¿ÞÂÊ ¸Þ´º ŸÀÌƲ À̹ÌÁö
°øÁö»çÇ×

Home < ¿­¸°¸¶´ç < °øÁö»çÇ×

       2012 È£¾Ï ÀÇÇлó ¼ö»óÀÚ(Á¤Àç¿õ ¹Ú»ç) ±â³ä °­¿¬È¸ °³ÃÖ ¾È³»
               
       biodesign        2012.04.30 16:51        5550
 
1. ¼ö»óÀÚ/°­¿¬ÀÚ: Á¤Àç¿õ ¹Ú»ç (Ú¸ ³²°¡ÁÖ´ë KECK ÀÇ´ë ±³¼ö, KAIST »ý¸í°úÇаú °âÀÓ±³¼ö) 2. ÀϽÃ: 2012. 5. 2 (¼ö) ¿ÀÈÄ 4½Ã 3. Àå¼Ò: KAIST KIºôµù(E4) 1Ãþ Ç»ÀüȦ 4. ÁÖÃÖ: KAIST »ý¸í°úÇаú, KI ¹ÙÀÌ¿ÀÀ¶ÇÕ¿¬±¸¼Ò, ISBC ±Û·Î¹úÇÁ·ÐƼ¾î ¿¬±¸´Ü, KAIST-USC ±Û·Î¹ú¿¬±¸¼Ò, È£¾ÏÀç´Ü * °­¿¬ Á¦¸ñ ¹× ÃÊ·Ï Host-Pathogen Standoff: Roles of Pattern Recognizing Receptors and Intracellular Restriction Factors in Antiviral Immune Response Understanding the host-viral interaction is an essential step in developing safe and effective anti-microbials against viruses. Since virus is most vulnerable at the early stage of lifecycle, this stage should therefore offer the best opportunity for therapeutic interventions. The early detection of invading viruses by the host depends on a limited number of Pattern Recognizing Receptors (PRRs) that serve as the primary intracellular sensors for viral specific genetic patterns and activate signal transduction cascades, thereby triggering interferon (IFN)-mediated antiviral defense mechanisms. Key virus-detecting PRRs include the nucleic acid-recognizing Toll-like receptors and the cytosolic RNA receptors RIG-I and MDA-5. Specifically, RIG-I has emerged as a key receptor in sensing viruses, including the influenza virus and hepatitis virus C (HCV), whereas MDA5 responds to the infection of picornaviruses and noroviruses. Upon viral infection, RIG-I undergoes the multiple step processes of ATP-dependent structural and functional activations to elicit IFN-mediated antiviral signal transduction. In addition, members of the tripartite motif (TRIM) proteins and the Linear Ubiquitination Assembly Complex (LUBAC) proteins also play major roles in the IFN-mediated inhibition of the lifecycles of viruses. Following the PRR-mediated viral sensing, hosts subsequently elicit intracellular



Total:64 page:(4/4)
16 Á¤º¸ ISBC [°úÁ¦°ø°í] (Àç)¹ÙÀÌ¿ÀÇÕ¼º¿¬±¸´Ü 2´Ü°è 1Â÷³âµµ .. 13.07.11 8058
15 Á¤º¸ ISBC (Àç)¹ÙÀÌ¿ÀÇÕ¼º¿¬±¸´Ü 1´Ü°è ÀÚü ´Ü°èÆò°¡ ½Ç½Ã .. 13.05.08 7366
14 Á¤º¸ ISBC °øµ¿Àåºñ ÀÌ¿ë¼ö°¡Ç¥ (2013.1.1 ±âÁØ) 13.01.11 8976
13 Á¤º¸ ISBC [¹ÙÀÌ¿ÀÇÕ¼º¿¬±¸´Ü] 1´Ü°è 2Â÷³âµµ ¿¬±¸´Ü ¿öÅ©¼ó.. 12.11.29 7142
12 Á¤º¸ ISBC [Á÷¿ø°ø°í] (Àç)¹ÙÀÌ¿ÀÇÕ¼º¿¬±¸´Ü Á÷¿ø ¸ðÁý °ø°í 12.11.08 7111
11 Á¤º¸ ISBC (Àç)¹ÙÀÌ¿ÀÇÕ¼º¿¬±¸´Ü 2012³âµµ ½Å±Ô°úÁ¦ ¼±Á¤ °ø.. 12.10.22 6237
10 Á¤º¸ ISBC [ä¿ë°ø°í] (Àç)¹ÙÀÌ¿ÀÇÕ¼º¿¬±¸´Ü ¿¬±¸¿ø ¸ðÁý 12.09.17 7027
9 Á¤º¸ ISBC [ä¿ë°ø°í] (Àç)¹ÙÀÌ¿ÀÇÕ¼º¿¬±¸´Ü Á÷¿ø ¸ðÁý 12.08.31 5800
8 Á¤º¸ ISBC (Àç)¹ÙÀÌ¿ÀÇÕ¼º¿¬±¸´Ü 1´Ü°è 2Â÷³âµµ ½Å±Ô°úÁ¦ °ø.. 12.08.31 7288
7 Á¤º¸ ISBC (Àç)¹ÙÀÌ¿ÀÇÕ¼º¿¬±¸´Ü ¿öÅ©¼ó °³ÃÖ ¾È³»('12.08.2.. 12.07.31 6092
6 Á¤º¸ biodesig 2012³â Áö´ÉÇü ¹ÙÀÌ¿À ½Ã½ºÅÛ ¼³°è ¹× ÇÕ¼º ¿¬±¸.. 12.07.02 5565
5 Á¤º¸ biodesig Áö´ÉÇü ¹ÙÀÌ¿À½Ã½ºÅÛ ¼³°è ¹× ÇÕ¼º ¿¬±¸ ¹Ì·¡±â¼ú.. 12.05.22 5725
4 Á¤º¸ biodesig 2012 È£¾Ï ÀÇÇлó ¼ö»óÀÚ(Á¤Àç¿õ ¹Ú»ç) ±â³ä °­¿¬.. 12.04.30 5551
3 Á¤º¸ ¼Ò³ª¹« ¿¬±¸Ã¥ÀÓÀÚ ¿÷¼¥ ¾È³» 12.03.28 6632
2 Á¤º¸ ¼Ò³ª¹« Áö´ÉÇü ¹ÙÀÌ¿À ½Ã½ºÅÛ ¼³°è ¹× ÇÕ¼º ¿¬±¸´Ü °³¼Ò.. 12.03.28 10709
1 Á¤º¸ ¼Ò³ª¹« ¿¬±¸´Ü ȨÆäÀÌÁö ¿ÀÇÂ! 12.03.28 7075
[1] [2] [3] [4]